Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics
Tài liệu tham khảo
Adar, 2012, Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers, Cell Death Dis., 3, pe293, 10.1038/cddis.2012.30
Albini, 2007, The tumour microenvironment as a target for chemoprevention, Nat. Rev. Cancer, 7, 139, 10.1038/nrc2067
Alkema, 2016, Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: different models for different questions, Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother., 24, 55, 10.1016/j.drup.2015.11.005
Alli, 2002, Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer, Cancer Res., 62, 6864
Anand, 2003, AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol, Cancer Cell, 3, 51, 10.1016/S1535-6108(02)00235-0
Assaraf, 2007, Molecular basis of antifolate resistance, Cancer Metast. Rev., 26, 153, 10.1007/s10555-007-9049-z
Assaraf, 2006, The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis, Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother., 9, 227, 10.1016/j.drup.2006.09.001
Assaraf, 1997, Loss of folic acid exporter function with markedly augmented folate accumulation in lipophilic antifolate-resistant mammalian cells, J. Biol. Chem., 272, 17460, 10.1074/jbc.272.28.17460
Bai, 2015, Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer, Int. J. Clin. Exp. Pathol., 8, 12333
Bandyopadhyay, 2011, Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines, Biochemistry, 50, 704, 10.1021/bi101110e
Bandyopadhyay, 2012, CK2-mediated hyperphosphorylation of topoisomerase I targets serine 506, enhances topoisomerase I-DNA binding, and increases cellular camptothecin sensitivity, PLoS One, 7, e50427, 10.1371/journal.pone.0050427
Berger, 1996, Structure and mechanism of DNA topoisomerase II, Nature, 379, 225, 10.1038/379225a0
Binenbaum, 2015, Gemcitabine resistance in pancreatic ductal adenocarcinoma, Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother., 23, 55, 10.1016/j.drup.2015.10.002
Bonneau, 2015, Predictive and prognostic value of the tauprotein in breast cancer, Anticancer Res., 35, 5179
Borst, 2000, A family of drug transporters: the multidrug resistance-associated proteins, J. Natl. Cancer Inst., 92, 1295, 10.1093/jnci/92.16.1295
Bouchalova, 2014, Triple negative breast cancer – BCL2 in prognosis and prediction, Curr. Drug Targets, 15, 1166, 10.2174/1389450115666141106151143
Bowden, 2014, Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?, Cancer Lett., 346, 163, 10.1016/j.canlet.2014.01.005
Bulgar, 2012, Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair, Cell Death Dis., 3, pe252, 10.1038/cddis.2011.135
Burgess, 2008, Topoisomerase levels determine chemotherapy response in vitro and in vivo, Proc. Natl. Acad. Sci. U. S. A., 105, 9053, 10.1073/pnas.0803513105
Callaghan, 2014, Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?, Drug Metab. Dispos.: Biol. Fate Chem., 42, 623, 10.1124/dmd.113.056176
Cao, 2012, Improved chemotherapy for hepatocellular carcinoma, Anticancer Res., 32, 1379
Carmena, 2012, The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis, Nat Rev Mol Cell Biol, 13, 789, 10.1038/nrm3474
Cayre, 2002, O(6)-methylguanine-DNA methyl transferase gene expression and prognosis in breast carcinoma, Int. J. Oncol., 21, 1125
Ceccaldi, 2015, A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance, Cancer Res., 75, 628, 10.1158/0008-5472.CAN-14-2593
Chapman, 2012, Playing the end game: DNA double-strand break repair pathway choice, Mol. Cell, 47, 497, 10.1016/j.molcel.2012.07.029
Chattopadhyay, 2007, Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability, Oncologist, 12, 808, 10.1634/theoncologist.12-7-808
ClinicalTrial, 2015
Coon, 2002, Amplification and overexpression of topoisomerase IIα predict response to anthracycline-based therapy in locally advanced breast cancer, Clin. Cancer Res., 8, 1061
Cunningham, 2004, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer, N. Engl. J. Med., 351, 337, 10.1056/NEJMoa033025
Czabotar, 2014, Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy, Nat. Rev. Mol. Cell Biol., 15, 49, 10.1038/nrm3722
De Donato, 2012, Class III beta-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer, J. Cell. Physiol., 227, 1034, 10.1002/jcp.22813
Dear, 2013, Combination versus sequential single agent chemotherapy for metastatic breast cancer, Cochr. Database Syst. Rev., 12, pCd008792
Delaney, 2000, Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines, Clin. Cancer res.: off. J. Am. Assoc. Cancer Res., 6, 2860
Ditchfield, 2003, Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores, J. Cell Biol., 161, 267, 10.1083/jcb.200208091
Drori, 2000, Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake, J. Biol. Chem., 275, 30855, 10.1074/jbc.M003988200
Dumontet, 2010, Microtubule-binding agents: a dynamic field of cancer therapeutics, Nat. Rev. Drug Discov., 9, 790, 10.1038/nrd3253
Edwards, 2008, Resistance to therapy caused by intragenic deletion in BRCA2, Nature, 451, 1111, 10.1038/nature06548
Elmore, 2007, Apoptosis: a review of programmed cell death, Toxicol. Pathol., 35, 495, 10.1080/01926230701320337
Emadi, 2009, Cyclophosphamide and cancer: golden anniversary, Nat. Rev. Clin. Oncol., 6, 638, 10.1038/nrclinonc.2009.146
Farmer, 2005, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, 434, 917, 10.1038/nature03445
Ferreira, 2016, Mechanisms of cisplatin resistance and targeting of cancer stem cells: adding glycosylation to the equation, Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother., 24, 34, 10.1016/j.drup.2015.11.003
Fink, 1996, The role of DNA mismatch repair in platinum drug resistance, Cancer Res., 56, 4881
Fischer, 2015, Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance, Nature, 527, 472, 10.1038/nature15748
Formentini, 2004, Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review, Langenbeck's Arch. Surg./Deutsche Gesellschaft Chirurgie, 389, 405, 10.1007/s00423-004-0510-y
Fujita, 2010, Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy, Neoplasia (New York, NY), 12, 807, 10.1593/neo.10458
Furlong, 2012, Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer, J. Pathol., 226, 746, 10.1002/path.3035
Galluzzi, 2012, Molecular mechanisms of cisplatin resistance, Oncogene, 31, 1869, 10.1038/onc.2011.384
Galluzzi, 2014, Systems biology of cisplatin resistance: past, present and future, Cell Death Dis., 5, pe1257, 10.1038/cddis.2013.428
Ganguly, 2011, Overexpression of mitotic centromere-associated Kinesin stimulates microtubule detachment and confers resistance to paclitaxel, Mol. Cancer Ther., 10, 929, 10.1158/1535-7163.MCT-10-1109
Gao, 2009, Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells, Cancer Biol. Ther., 8, 1671, 10.4161/cbt.8.17.9322
Gao, 2013, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci Signal, 6, pl1, 10.1126/scisignal.2004088
Gatti, 2015, New mechanisms for old drugs: Insights into DNA-unrelated effects of platinum compounds and drug resistance determinants, Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother., 20, 1, 10.1016/j.drup.2015.04.001
Giannakakou, 1997, Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization, J. Biol. Chem., 272, 17118, 10.1074/jbc.272.27.17118
Gianni, 2008, Anthracycline cardiotoxicity: from bench to bedside, J. Clin. Oncol., 26, 3777, 10.1200/JCO.2007.14.9401
Giovannetti, 2006, Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine, Cancer Res., 66, 3928, 10.1158/0008-5472.CAN-05-4203
Gonen, 2012, Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance, Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother., 15, 183, 10.1016/j.drup.2012.07.002
Gorlick, 1997, Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression, Blood, 89, 1013, 10.1182/blood.V89.3.1013
Gottesman, 2002, Multidrug resistance in cancer: role of ATP-dependent transporters, Nat. Rev. Cancer, 2, 48, 10.1038/nrc706
Greenhalf, 2014, Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial, J. Natl. Cancer Inst., 106, pdjt347, 10.1093/jnci/djt347
Guo, 1999, Mechanisms of methotrexate resistance in osteosarcoma, Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res., 5, 621
Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013
Hande, 1998, Clinical applications of anticancer drugs targeted to topoisomerase II, Biochim. Biophys. Acta (BBA) – Gene Struct. Expr., 1400, 173, 10.1016/S0167-4781(98)00134-1
Hari, 2006, Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules, Mol. Cancer Ther., 5, 270, 10.1158/1535-7163.MCT-05-0190
Hazar-Rethinam, 2015, RacGAP1 is a novel downstream effector of E2F7-dependent resistance to doxorubicin and is prognostic for overall survival in squamous cell carcinoma, Mol. Cancer Therapeut., 14, 1939, 10.1158/1535-7163.MCT-15-0076
Hazar-Rethinam, 2015, A novel E2F/sphingosine kinase 1 axis regulates anthracycline response in squamous cell carcinoma, Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res., 21, 417, 10.1158/1078-0432.CCR-14-1962
Herlevsen, 2007, Depletion of major vault protein increases doxorubicin sensitivity and nuclear accumulation and disrupts its sequestration in lysosomes, Mol. Cancer Therapeut., 6, 1804, 10.1158/1535-7163.MCT-06-0372
Hofree, 2013, Network-based stratification of tumor mutations, Nat. Methods, 10, 1108, 10.1038/nmeth.2651
Holm, 1989, Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells, Cancer Res., 49, 6365
Holohan, 2013, Cancer drug resistance: an evolving paradigm, Nat. Rev. Cancer, 13, 714, 10.1038/nrc3599
Horisberger, 2009, Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer, Anticancer Drugs, 20, 519, 10.1097/CAD.0b013e32832b53ff
Horwitz, 1973, Effects of camptothecin on the breakage and repair of DNA during the cell cycle, Cancer Res., 33, 2834
Hsiang, 1985, Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I, J. Biol. Chem., 260, 14873, 10.1016/S0021-9258(17)38654-4
Hsiang, 1989, Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin, Cancer Res., 49, 5077
Huang, 2014, Nucleotide excision repair gene polymorphisms and prognosis of non-small cell lung cancer patients receiving platinum-based chemotherapy: a meta-analysis based on 44 studies, Biomed. Rep., 2, 452, 10.3892/br.2014.282
Huang, 2012, MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling, Cell, 151, 937, 10.1016/j.cell.2012.10.035
Huang, 2013, Expression of survivin and patients survival in non-small cell lung cancer: a meta-analysis of the published studies, Mol. Biol. Rep., 40, 917, 10.1007/s11033-012-2132-8
Hung, 2015, p22phox confers resistance to cisplatin, by blocking its entry into the nucleus, Oncotarget, 6, 4110, 10.18632/oncotarget.2893
Igney, 2002, Death and anti-death: tumour resistance to apoptosis, Nat. Rev. Cancer, 2, 277, 10.1038/nrc776
Iida, 2013, Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment,, Science (New York, NY), 342, 967, 10.1126/science.1240527
Ikeguchi, 2011, Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer, Surg. Today, 41, 1196, 10.1007/s00595-011-4546-7
Ivy, 2013, A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells, Mol. Pharmacol., 83, 1237, 10.1124/mol.113.085068
Jabeen, 2015, Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate, Pharmacogenom. J., 15, 385, 10.1038/tpj.2015.11
Jansen, 1998, A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance, J. Biol. Chem., 273, 30189, 10.1074/jbc.273.46.30189
Januchowski, 2013, The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance, Biomed. Pharmacother.=Biomed. Pharmacother., 67, 669, 10.1016/j.biopha.2013.04.005
Järvinen, 1996, Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer, Am. J. Pathol., 148, 2073
Jia, 2015, p57Kip2 is an unrecognized DNA damage response effector molecule that functions in tumor suppression and chemoresistance, Oncogene, 34, 3568, 10.1038/onc.2014.287
Jiang, 2014, Enriched variations in TEKT4 and breast cancer resistance to paclitaxel, Nat. Commun., 5, 3802, 10.1038/ncomms4802
Jing, 2011, Opposing roles of NF-kappaB in anti-cancer treatment outcome unveiled by cross-species investigations, Genes Dev., 25, 2137, 10.1101/gad.17620611
Johnson, 2013, CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia, Blood, 122, 4253, 10.1182/blood-2013-07-516666
Kamal, 2010, MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer, Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res., 16, 1206, 10.1158/1078-0432.CCR-09-2204
Kanakkanthara, 2013, Cytoskeletal alterations that confer resistance to anti-tubulin chemotherapeutics, Anticancer Agents Med. Chem., 13, 147, 10.2174/187152013804487263
Kang, 2013, Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer, J. Natl. Cancer Inst., 105, 1485, 10.1093/jnci/djt210
Kar, 2003, Repeat motifs of tau bind to the insides of microtubules in the absence of taxol, Embo. J., 22, 70, 10.1093/emboj/cdg001
Karki, 2013, betaIII-Tubulin: biomarker of taxane resistance or drug target?, Expert Opin. Therapeut. Targets, 17, 461, 10.1517/14728222.2013.766170
Kathawala, 2015, The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade, Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother., 18, 1, 10.1016/j.drup.2014.11.002
Kavallaris, 2010, Microtubules and resistance to tubulin-binding agents, Nat. Rev. Cancer, 10, 194, 10.1038/nrc2803
Kawahara, 2009, Higher expression of deoxyuridine triphosphatase (dUTPase) may predict the metastasis potential of colorectal cancer, J. Clin. Pathol., 62, 364, 10.1136/jcp.2008.060004
Kelly, 2006, TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer, Cancer Res., 66, 3859, 10.1158/0008-5472.CAN-05-3948
Kim, 2011, A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients, PLoS ONE, 6, pe16694, 10.1371/journal.pone.0016694
Kim, 2016, Targeting EZH2 in cancer, Nat. Med., 22, 128, 10.1038/nm.4036
Knuefermann, 2003, HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells, Oncogene., 22, 3205, 10.1038/sj.onc.1206394
Koehler, 2004, Small interfering RNA-mediated suppression of dUTPase sensitizes cancer cell lines to thymidylate synthase inhibition, Mol. Pharmacol., 66, 620
Koster, 2013, Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer, Expert Rev. Mol. Med., 15, pe12, 10.1017/erm.2013.13
Kroemer, 2013, Immunogenic cell death in cancer therapy, Annu. Rev. Immunol., 31, 51, 10.1146/annurev-immunol-032712-100008
Kuang, 2015, Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients, Oncotarget, 6, 22227, 10.18632/oncotarget.4276
Lai, 2011, Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF, Cancer Res., 71, 2728, 10.1158/0008-5472.CAN-10-2711
Leinonen, 2014, Role of the Keap1-Nrf2 pathway in cancer, Adv. Cancer Res., 122, 281, 10.1016/B978-0-12-420117-0.00008-6
Leong, 2007, The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers, J. Clin. investig., 117, 1370, 10.1172/JCI30866
Li, 2014, Prognostic significance of survivin in breast cancer: meta-analysis, Breast J., 20, 514, 10.1111/tbj.12303
Li, 2014, FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin, J. Cell Mol. Med., 18, 811, 10.1111/jcmm.12216
Li, 2010, Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy, Biochim. Biophys. Acta, 1805, 167
Liu, 2013, FPGS rs1544105 polymorphism is associated with treatment outcome in pediatric B-cell precursor acute lymphoblastic leukemia, Cancer Cell Int., 13, p107, 10.1186/1475-2867-13-107
Livney, 2013, Rationally designed nanovehicles to overcome cancer chemoresistance, Adv. Drug Deliv. Rev., 65, 1716, 10.1016/j.addr.2013.08.006
Loi, 2013, CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer, Proc. Natl. Acad. Sci. U. S. A., 110, 11091, 10.1073/pnas.1222251110
Mackey, 1998, Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines, Cancer Res., 58, 4349
Marechal, 2009, Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma, Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res., 15, 2913, 10.1158/1078-0432.CCR-08-2080
Mayer, 2014, New strategies for triple-negative breast cancer – deciphering the heterogeneity, Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res., 20, 782, 10.1158/1078-0432.CCR-13-0583
Mazzanti, 2008, Hepatocellular carcinoma: epidemiology and clinical aspects, Mol. Aspects Med., 29, 130, 10.1016/j.mam.2007.09.008
McCarroll, 2010, betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer, Cancer Res., 70, 4995, 10.1158/0008-5472.CAN-09-4487
Meisenberg, 2015, Clinical and cellular roles for TDP1 and TOP1 in modulating colorectal cancer response to irinotecan, Mol. Cancer Therapeut., 14, 575, 10.1158/1535-7163.MCT-14-0762
Minotti, 2004, Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity, Pharmacol. Rev., 56, 185, 10.1124/pr.56.2.6
Miyashita, 1992, bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs, Cancer Res., 52, 5407
Miyoshi, 2010, Predictive factors for anthracycline-based chemotherapy for human breast cancer, Breast Cancer (Tokyo Japan), 17, 103, 10.1007/s12282-009-0152-6
Mlak, 2015, The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient, Clin. Transl. Oncol.: Off. Pub. Fed. Spanish Oncol. Soc. Natl. Cancer Inst. Mexico
Mokady, 2015, RhoGTPases – a novel link between cytoskeleton organization and cisplatin resistance, Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother., 19, 22, 10.1016/j.drup.2015.01.001
Monteiro, 2013, The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment, Oncogene, 32, 4634, 10.1038/onc.2012.491
Morth, 2014, Single-agent versus combination chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer and performance status 2: a literature-based meta-analysis of randomized studies, Lung Cancer (Amst. Neth.), 84, 209, 10.1016/j.lungcan.2014.03.015
Mu, 2015
Ni Chonghaile, 2011, Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy, Science (New York, NY), 334, 1129, 10.1126/science.1206727
Nitiss, 2009, Targeting DNA topoisomerase II in cancer chemotherapy, Nat. Rev. Cancer, 9, 338, 10.1038/nrc2607
Nobili, 2011, Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer, Int. J. Cancer. J. Int. Cancer, 128, 1935, 10.1002/ijc.25514
Nordh, 2014, hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review, World J. Gastroenterol., 20, 8482, 10.3748/wjg.v20.i26.8482
Norquist, 2011, Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas, J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol., 29, 3008, 10.1200/JCO.2010.34.2980
Ohno, 2006, Loss of O6-methylguanine-DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large B-cell lymphoma, Int. J. Hematol., 83, 341, 10.1532/IJH97.05182
Organista-Nava, 2010, Polymorphisms of the gamma-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico, Leukem. Res., 34, 728, 10.1016/j.leukres.2009.11.027
Pang, 2015, Chemical profiling of the genome with anti-cancer drugs defines target specificities, Nat. Chem. Biol., 11, 472, 10.1038/nchembio.1811
Pang, 2013, Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin, Nat. Commun., 4, p1908, 10.1038/ncomms2921
Park, 2002, X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance, Cancer Res., 62, 459
Pastor-Anglada, 2015, Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets, Front. Pharmacol., 6, p13, 10.3389/fphar.2015.00013
Patankar, 2013, Topotecan and doxorubicin combination to treat recurrent ovarian cancer: the influence of drug exposure time and delivery systems to achieve optimum therapeutic activity, Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res., 19, 865, 10.1158/1078-0432.CCR-12-2459
Patutina, 2010, The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy, BMC Cancer, 10, p204, 10.1186/1471-2407-10-204
Pirker, 2012, EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study, Lancet Oncol., 13, 33, 10.1016/S1470-2045(11)70318-7
Planells-Cases, 2015, Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs, EMBO J., 34, 2993, 10.15252/embj.201592409
Pommier, 2013, Drugging topoisomerases: lessons and challenges, ACS Chem. Biol., 8, 82, 10.1021/cb300648v
Pommier, 1999, Topoisomerase I inhibitors: selectivity and cellular resistance, Drug Resist Updat, 2, 307, 10.1054/drup.1999.0102
Pritchard, 2012, Understanding resistance to combination chemotherapy, Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother., 15, 249, 10.1016/j.drup.2012.10.003
Qiu, 2006, Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption, Cell, 127, 917, 10.1016/j.cell.2006.09.041
Raz, 2014, Binding of a Smad4/Ets-1 complex to a novel intragenic regulatory element in exon12 of FPGS underlies decreased gene expression and antifolate resistance in leukemia, Oncotarget, 5, 9183, 10.18632/oncotarget.2399
Raz, 2016, Folylpoly-γ-glutamate synthetase: a key determinant of folate homeostasis and antifolate resistance in cancer, Drug Resist. Updates, 10.1016/j.drup.2016.06.004
Rebucci, 2013, Molecular aspects of cancer cell resistance to chemotherapy, Biochem. Pharmacol., 85, 1219, 10.1016/j.bcp.2013.02.017
Regev, 1997, Flip-flop of doxorubicin across erythrocyte and lipid membranes, Biochem. Pharmacol., 54, 1151, 10.1016/S0006-2952(97)00326-2
Regev, 2005, Transport of anthracyclines and mitoxantrone across membranes by a flip-flop mechanism, Biochem. Pharmacol., 70, 161, 10.1016/j.bcp.2005.03.032
Rothem, 2002, Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines, Biochem. J., 367, 741, 10.1042/bj20020801
Rots, 1999, Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia, Blood, 93, 1677, 10.1182/blood.V93.5.1677
Rouzier, 2005, Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer, Proc Natl Acad Sci U S A, 102, 8315, 10.1073/pnas.0408974102
Sakai, 2008, Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers, Nature, 451, 1116, 10.1038/nature06633
Salonga, 2000, Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase, Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res., 6, 1322
Sawant, 2015, Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links, DNA Rep., 35, 126, 10.1016/j.dnarep.2015.10.003
Schellens, 2000, Transport of topoisomerase I inhibitors by the breast cancer resistance protein potential clinical implications, Ann. N Y Acad. Sci., 922, 188, 10.1111/j.1749-6632.2000.tb07037.x
Schramm, 2015, Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review. Breast Care (Basel), 10, 173
Schumacher, 2015, Neoantigens in cancer immunotherapy, Science (New York, NY), 348, 69, 10.1126/science.aaa4971
Serdjebi, 2015, Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs, Expert Opin. Drug Metab. Toxicol., 11, 665, 10.1517/17425255.2015.985648
Shapira, 2011, Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance, Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother., 14, 150, 10.1016/j.drup.2011.01.003
Sharma, 2010, A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations, Cell, 141, 69, 10.1016/j.cell.2010.02.027
Siddik, 2003, Cisplatin: mode of cytotoxic action and molecular basis of resistance, Oncogene, 22, 7265, 10.1038/sj.onc.1206933
Sinnott, 2014, Mechanisms promoting escape from mitotic stress-induced tumor cell death, Cancer Res., 74, 3857, 10.1158/0008-5472.CAN-13-3398
Sladek, 2002, Cancer Chemother. Pharmacol., 49, 309, 10.1007/s00280-001-0412-4
Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N. Engl. J. Med., 344, 783, 10.1056/NEJM200103153441101
Smith, 2012, Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia, Nature, 485, 260, 10.1038/nature11016
Smoter, 2013, Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy, J. Exp. Clin. Cancer Res., 32, 25, 10.1186/1756-9966-32-25
Souers, 2013, ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, Nat. Med., 19, 202, 10.1038/nm.3048
Spratlin, 2004, The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma, Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res., 10, 6956, 10.1158/1078-0432.CCR-04-0224
Stark, 2003, Antifolate resistance associated with loss of MRP1 expression and function in Chinese hamster ovary cells with markedly impaired export of folate and cholate, Mol. Pharmacol., 64, 220, 10.1124/mol.64.2.220
Stewart, 1998, A model for the mechanism of human topoisomerase I, Science, 279, 1534, 10.1126/science.279.5356.1534
Sudo, 2004, Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint, Cancer Res., 64, 2502, 10.1158/0008-5472.CAN-03-2013
Szakacs, 2006, Targeting multidrug resistance in cancer, Nat. Rev. Drug Discov., 5, 219, 10.1038/nrd1984
Taddia, 2015, Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: novel strategies to overcome cancer chemoresistance, Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother., 23, 20, 10.1016/j.drup.2015.10.003
Tang, 2015, SLFN11 Is a transcriptional target of EWS-FLI1 and a determinant of drug response in Ewing sarcoma, Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res., 21, 4184, 10.1158/1078-0432.CCR-14-2112
Tiwari, 2013, Overlapping functions of ABC transporters in topotecan disposition as determined in gene knockout mouse models, Mol. Cancer Ther., 12, 1343, 10.1158/1535-7163.MCT-13-0100
Undevia, 2005, Pharmacokinetic variability of anticancer agents, Nat. Rev. Cancer, 5, 447, 10.1038/nrc1629
Van Allen, 2014, Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma, Cancer Discov., 4, 1140, 10.1158/2159-8290.CD-14-0623
van der Wilt, 2001, Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors, Cancer Res., 61, 3675
van Vuuren, 2015, Antimitotic drugs in the treatment of cancer, Cancer Chemother. Pharmacol., 76, 1101, 10.1007/s00280-015-2903-8
Vecchione, 2016, A vulnerability of a subset of colon cancers with potential clinical utility, Cell, 165, 317, 10.1016/j.cell.2016.02.059
Viaud, 2013, The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide, Science (New York, NY), 342, 971, 10.1126/science.1240537
Vidal, 2014, Targeting cancer stem cells to suppress acquired chemotherapy resistance, Oncogene, 33, 4451, 10.1038/onc.2013.411
Vogler, 2014, Targeting BCL2-proteins for the treatment of solid tumours, Adv. Med., 2014, p943648, 10.1155/2014/943648
Wang, 2002, Cellular roles of DNA topoisomerases: a molecular perspective, Nat. Rev. Mol. Cell Biol., 3, 430, 10.1038/nrm831
Wang, 2011, DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy, J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol., 29, 4121, 10.1200/JCO.2010.34.3616
Wang, 2011, Genetic polymorphisms of ERCC1 and their effects on the efficacy of cisplatin-based chemotherapy in advanced esophageal carcinoma, Oncol. Rep., 25, 1047
Waters, 2014, The FHIT gene product: tumor suppressor and genome “caretaker”, Cell. Mol. Life Sci.: CMLS, 71, 4577, 10.1007/s00018-014-1722-0
Wee, 2015, IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel, Nat. Commun., 6, 8746, 10.1038/ncomms9746
Weeks, 2013, Uracil-DNA glycosylase expression determines human lung cancer cell sensitivity to pemetrexed, Mol. Cancer Therapeut., 12, 2248, 10.1158/1535-7163.MCT-13-0172
Wei, 2013, A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers, Pancreas, 42, 1303, 10.1097/MPA.0b013e3182a23ae4
Wei, 2011, A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome, J. Hematol. Oncol., 4, 46, 10.1186/1756-8722-4-46
Weiss, 1992, The anthracyclines: will we ever find a better doxorubicin?, Semin. Oncol., 19, 670
Werner, 2014, Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer, PLoS One, 9, e90141, 10.1371/journal.pone.0090141
Whitehead, 1990, Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis, Blood, 76, 44, 10.1182/blood.V76.1.44.44
Wijdeven, 2015, Genome-wide identification and characterization of novel factors conferring resistance to topoisomerase II poisons in cancer, Cancer Res., 75, 4176, 10.1158/0008-5472.CAN-15-0380
Wilson, 2014, Standing the test of time: targeting thymidylate biosynthesis in cancer therapy, Nat. Rev. Clin. Oncol., 11, 282, 10.1038/nrclinonc.2014.51
Wilson, 2012, Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer, Mol. Cancer Therapeut., 11, 616, 10.1158/1535-7163.MCT-11-0781
Wojtuszkiewicz, 2015, Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia, J. Hematol. Oncol., 8, p61, 10.1186/s13045-015-0158-9
Wojtuszkiewicz, 2016, Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance, Int. J. Cancer. J. Int. Cancer, 138, 1645, 10.1002/ijc.29919
Wu, 2015, FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-kappaB/Slug-mediated PUMA reduction, Oncogene, 34, 2505, 10.1038/onc.2014.184
Xu, 2015, Proteomic profiling of paclitaxel treated cells identifies a novel mechanism of drug resistance mediated by PDCD4, J. Proteome. Res., 14, 2480, 10.1021/acs.jproteome.5b00004
Xu, 2015, Inhibition of topoisomerase (DNA) I (TOP1): DNA damage repair and anticancer therapy, Biomolecules, 5, 1652, 10.3390/biom5031652
Yang, 2013, Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: a systematic review and meta-analysis, J. Exp. Clin. Cancer Res.: CR, 32, 105, 10.1186/1756-9966-32-105
Yang, 2013, Doxorubicin enhances nucleosome turnover around promoters, Curr. Biol.: CB, 23, 782, 10.1016/j.cub.2013.03.043
Yatim, 2015, RIPK1 and NF-kappaB signaling in dying cells determines cross-priming of CD8(+) T cells, Science (New York, NY), 350, 328, 10.1126/science.aad0395
Yin, 2010, Human mutations that confer paclitaxel resistance, Mol. Cancer Ther., 9, 327, 10.1158/1535-7163.MCT-09-0674
Yu, 2015, Inhibition of spleen tyrosine kinase potentiates paclitaxel-induced cytotoxicity in ovarian cancer cells by stabilizing microtubules, Cancer Cell, 28, 82, 10.1016/j.ccell.2015.05.009
Zaffaroni, 2002, Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer, Cell Mol. Life Sci., 59, 1406, 10.1007/s00018-002-8518-3
Zarrinkar, 2009, AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML), Blood, 114, 2984, 10.1182/blood-2009-05-222034
Zhang, 2005, Insights into oxazaphosphorine resistance and possible approaches to its circumvention, Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother., 8, 271, 10.1016/j.drup.2005.08.003
Zhao, 2014, Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance, PLoS One, 9, e113478, 10.1371/journal.pone.0113478
Zheng, 2015, Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer, Nature, 527, 525, 10.1038/nature16064
Zhitomirsky, 2015, Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance, Oncotarget, 6, 1143, 10.18632/oncotarget.2732
Zhitomirsky, 2016, Lysosomes as mediators of drug resistance in cancer, Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother., 24, 23, 10.1016/j.drup.2015.11.004
Zoppoli, 2012, Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents, Proc. Natl. Acad. Sci. U. S. A., 109, 15030, 10.1073/pnas.1205943109